Figure 1

Days AdV-HBV (positive control) 6*10^3 cells/well

X Mean Upper Limit Lower Limit Mean Upper Limit Lower Limit
1 302.0 330.0 269.5 112.8 123.2 102.9
2 302.0 330.0 269.5 109.5 117.7 101.2
3 302.0 330.0 269.5 102.3 111.1 93
6 302.0 330.0 269.5 561 605 528
 10^4 cells/well 3*10^4 cells/well Non-template control (NTC)
Mean Upper Limit Lower Limit Mean Upper Limit Lower Limit Mean Upper Limit
92.4 100.1 85.3 233.2 255.2 211.8 0 0.61
133.1 145.2 119.9 419.7 451 390.5 0 0.61
331.7 348.2 315.2 693 753.5 632.5 0 0.61
1386 1441 1331 2260.5 2381.5 2128.5 0 0.61
plate control (NTC)
Lower Limit
0
0
0
0
Figure 2A

[Lamivudine], uM Day 8 Day 11 Day 14

X Mean Upper Limit Lower Limit Mean Upper Limit Lower Limit Mean
Untreated 1881.0 1969.0 1809.5 2310.0 2381.5 2233.0 4405.5
0.01 2161.5 2233.0 2095.5 2359.5 2464.0 2260.5 7925.5
0.1 1864.5 1936.0 1782.0 1908.5 1985.5 1820.5 4521.0
1 1760.0 1892.0 1617.0 1628.0 1666.5 1589.5 3767.5
10 2365.0 2568.5 2161.5 3151.5 3272.5 3041.5 5362.5
NTC 0.0 0.7 0.0 0.0 0.7 0.0 0.0

Figure 2B

[Tenofovir], uM Day 8 Day 11 Day 14

X Mean Upper Limit Lower Limit Mean Upper Limit Lower Limit Mean
Untreated 1754.5 1804.0 1699.5 2051.5 2090.0 2013.0 3701.5
0.01 1567.5 1606.0 1523.5 1584.0 1699.5 1474.0 2354.0
0.1 1485.0 1523.5 1446.5 1237.5 1298.0 1171.5 1985.5
1 1419.0 1485.0 1358.5 1364.0 1468.5 1265.0 1320.0
10 404.8 599.5 286.0 581.9 638.0 517.0 1072.5
NTC 0.0 0.7 0.0 0.0 0.7 0.0 0.0
 Day 14
Upper Limit Lower Limit
4515.5 4301.0
8090.5 7760.5
4625.5 4416.5
3872.0 3663.0
5500.0 5225.0
1.2 0.0

Day 14
Upper Limit Lower Limit
3795.0 3608.0
2431.0 2277.0
2051.5 1925.0
1375.0 1265.0
1116.5 1023.0
1.2 0.0
 Figure 3

[Concentration], uM 3TC TFV AT021 (10 u

X Mean Upper Limit Lower Limit Mean Upper Limit Lower Limit Mean
Untreated 2110.952 2179.048 2042.857 2687.143 2770.952 2608.571 3038.095
0.01 1938.095 2006.19 1875.238 2090 2158.095 2027.143 2765.714
0.1 2404.286 2472.381 2330.952 1838.571 1896.19 1786.19 2666.19
1 1880.476 1938.095 1817.619 1613.333 1665.714 1560.952 2613.81
10 1985.238 2048.095 1922.381 497.619 523.8095 471.4286 2362.381
NTC 0 0.66 0 0 0.66 0 0
AT021 (10 uM) AT021 (2,17 uM)
Upper Limit Lower Limit Mean Upper Limit Lower Limit
3121.905 2954.286 3823.81 3918.095 3729.524
2833.81 2692.381 3111.429 3200.476 3022.381
2739.524 2592.857 2849.524 2928.095 2770.952
2692.381 2540.476 2561.429 2634.762 2482.857
2425.238 2299.524 2320.476 2388.571 2247.143
0.66 0 0 0.66 0
 Anova: Single Factor

SUMMARY
Groups Count Sum Average Variance
[Lamivudin 6 10032 1672 720784.9
[Lamivudin 6 11357.5 1892.917 1125850

ANOVA
Source of VariationSS df MS F P-value F crit
Between G 146412.5 1 146412.5 0.158572 0.698843 4.964603
Within Gro 9233172 10 923317.2

Total 9379585 11

Anova: Single Factor

SUMMARY
Groups Count Sum Average Variance
[Tenofovir 6 6630.8 1105.133 518011.5
[Tenofovir 6 6818.9 1136.483 539730.4

ANOVA
Source of VariationSS df MS F P-value F crit
Between G 2948.468 1 2948.468 0.005575 0.941953 4.964603
Within Gro 5288709 10 528870.9

Total 5291658 11
[Concentration], uM 3TC TFV AT021 (10 uM)
X Mean Upper Limit
Lower Limit Mean Upper Limit
Lower Limit Mean Upper LimitLower Limit
Untreated 2110.952 2179.048 2042.857 2687.143 2770.952 2608.571 3038.095 3121.905 2954.286
0.01 1938.095 2006.19 1875.238 2090 2158.095 2027.143 2765.714 2833.81 2692.381
0.1 2404.286 2472.381 2330.952 1838.571 1896.19 1786.19 2666.19 2739.524 2592.857
1 1880.476 1938.095 1817.619 1613.333 1665.714 1560.952 2613.81 2692.381 2540.476
10 1985.238 2048.095 1922.381 497.619 523.8095 471.4286 2362.381 2425.238 2299.524
NTC 0 0.66 0 0 0.66 0 0 0.66 0

X 3TC TFV AT021 (10 AT021 (2,17 uM)

Untreated 2399.048 2399.048 3430.953 3430.953
0.01 1938.095 2090 2765.714 3111.429
0.1 2404.286 1838.571 2666.19 2849.524
1 1880.476 1613.333 2613.81 2561.429
10 1985.238 497.619 2362.381 2320.476
NTC 0 0 0 0

Figure 2A

[Lamivudine], uM Day 8 Day 11 Day 14

X Mean Upper Limit
Lower Limit Mean Upper Limit
Lower Limit Mean Upper Limit
Lower Limit
Untreated 1881.0 1969.0 1809.5 2310.0 2381.5 2233.0 4405.5 4515.5 4301.0
0.01 2161.5 2233.0 2095.5 2359.5 2464.0 2260.5 7925.5 8090.5 7760.5
0.1 1864.5 1936.0 1782.0 1908.5 1985.5 1820.5 4521.0 4625.5 4416.5
1 1760.0 1892.0 1617.0 1628.0 1666.5 1589.5 3767.5 3872.0 3663.0
10 2365.0 2568.5 2161.5 3151.5 3272.5 3041.5 5362.5 5500.0 5225.0
NTC 0.0 0.7 0.0 0.0 0.7 0.0 0.0 1.2 0.0

Figure 2B

[Tenofovir], uM Day 8 Day 11 Day 14

X Mean Upper Limit
Lower Limit Mean Upper Limit
Lower Limit Mean Upper Limit
Lower Limit
Untreated 1754.5 1804.0 1699.5 2051.5 2090.0 2013.0 3701.5 3795.0 3608.0
0.01 1567.5 1606.0 1523.5 1584.0 1699.5 1474.0 2354.0 2431.0 2277.0
0.1 1485.0 1523.5 1446.5 1237.5 1298.0 1171.5 1985.5 2051.5 1925.0
1 1419.0 1485.0 1358.5 1364.0 1468.5 1265.0 1320.0 1375.0 1265.0
10 404.8 599.5 286.0 581.9 638.0 517.0 1072.5 1116.5 1023.0
NTC 0.0 0.7 0.0 0.0 0.7 0.0 0.0 1.2 0.0
 AT021 (2,17 uM)
Mean Upper LimitLower Limit
3823.81 3918.095 3729.524
3111.429 3200.476 3022.381
2849.524 2928.095 2770.952
2561.429 2634.762 2482.857
2320.476 2388.571 2247.143
0 0.66 0

[Lamivudine],
[Lamivudine], uM uM[Lamivudin
Day 8 [Lamivudine], uM Day 14
Lower Limit Untreated 1881.0 2310.0 4405.5
0.01 2161.5 2359.5 7925.5
0.1 1864.5 1908.5 4521.0
1 1760.0 1628.0 3767.5
10 2365.0 3151.5 5362.5
NTC 0.0 0.0 0.0

[Tenofovir [Tenofovir [Tenofovir], uM Day 14

[Tenofovir], uM
Lower Limit Untreated 1754.5 2051.5 3701.5
0.01 1567.5 1584.0 2354.0
0.1 1485.0 1237.5 1985.5
1 1419.0 1364.0 1320.0
10 404.8 581.9 1072.5
NTC 0.0 0.0 0.0
 Dose Drug Response
Untreated 3TC 2399.048
0.01 3TC 1938.095
0.1 3TC 2404.286
1 3TC 1880.476
10 3TC 1985.238
NTC 3TC 0
Untreated TFV 2399.048
0.01 TFV 2090
0.1 TFV 1838.571
1 TFV 1613.333
10 TFV 497.619
NTC TFV 0
Untreated AT021 (10 3430.953
0.01 AT021 (10 2765.714
0.1 AT021 (10 2666.19
1 AT021 (10 2613.81
10 AT021 (10 2362.381
NTC AT021 (10 0
Untreated AT021 (2,1 3430.953
0.01 AT021 (2,1 3111.429
0.1 AT021 (2,1 2849.524
1 AT021 (2,1 2561.429
10 AT021 (2,1 2320.476
NTC AT021 (2,1 0